ALPS Advisors’s ChemoCentryx, Inc. CCXI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-38,984
| Closed | -$2.01M | – | 1109 |
|
|
2022
Q3 | $2.01M | Sell |
38,984
-3,254
| -8% | -$134K | 0.02% | 309 |
|
|
2022
Q2 | $1.05M | Sell |
42,238
-30,564
| -42% | -$674K | 0.01% | 466 |
|
|
2022
Q1 | $1.82M | Sell |
72,802
-8,238
| -10% | -$232K | 0.02% | 229 |
|
|
2021
Q4 | $2.95M | Sell |
81,040
-4,638
| -5% | -$163K | 0.03% | 198 |
|
|
2021
Q3 | $1.47M | Sell |
85,678
-6,186
| -7% | -$96.4K | 0.01% | 351 |
|
|
2021
Q2 | $1.23M | Sell |
91,864
-34,078
| -27% | -$840K | 0.01% | 379 |
|
|
2021
Q1 | $6.45M | Buy |
125,942
+1,419
| +1% | +$85.4K | 0.06% | 161 |
|
|
2020
Q4 | $7.71M | Buy |
124,523
+36,670
| +42% | +$2.1M | 0.09% | 151 |
|
|
2020
Q3 | $4.81M | Buy |
87,853
+3,473
| +4% | +$187K | 0.07% | 162 |
|
|
2020
Q2 | $4.86M | Sell |
84,380
-21,258
| -20% | -$1.16M | 0.07% | 154 |
|
|
2020
Q1 | $4.25M | Sell |
105,638
-11,650
| -10% | -$495K | 0.07% | 153 |
|
|
2019
Q4 | $4.64M | Buy |
117,288
+1,179
| +1% | +$20.7K | 0.04% | 164 |
|
|
2019
Q3 | $787K | Sell |
116,109
-5,384
| -4% | -$40.4K | 0.01% | 348 |
|
|
2019
Q2 | $1.13M | Sell |
121,493
-546
| -0.4% | -$6.32K | 0.01% | 302 |
|
|
2019
Q1 | $1.7M | Sell |
122,039
-34,520
| -22% | -$395K | 0.01% | 246 |
|
|
2018
Q4 | $1.71M | Buy |
156,559
+25,630
| +20% | +$270K | 0.01% | 235 |
|
|
2018
Q3 | $1.66M | Buy |
130,929
+23,698
| +22% | +$286K | 0.01% | 274 |
|
|
2018
Q2 | $1.41M | Buy |
107,231
+69,640
| +185% | +$833K | 0.01% | 271 |
|
|
2018
Q1 | $511K | Buy |
+37,591
| New | +$388K | ﹤0.01% | 503 |
|
|
2017
Q2 | – | Sell |
-41,127
| Closed | -$299K | – | 793 |
|
|
2017
Q1 | $299K | Sell |
41,127
-4,815
| -10% | -$34.7K | ﹤0.01% | 690 |
|
|
2016
Q4 | $340K | Buy |
+45,942
| New | +$331K | ﹤0.01% | 656 |
|
Other funds holding CCXI
ALPS Advisors's CCXI Position: Q4 2022 in Review
ALPS Advisors sold out of ChemoCentryx, Inc. (CCXI) in Q4 2022, closing a stake of 38,984 shares — an estimated $2.01M sold.
ALPS Advisors first reported a position in CCXI in Q4 2016 and held it in 21 quarters. The position peaked at $7.71M in Q4 2020. 1 fund tracked by Wall St. Rank holds CCXI as of Q4 2022.
- ALPS Advisors reported no remaining ChemoCentryx, Inc. position as of Q4 2022 after selling out during the quarter.
- ALPS Advisors sold 38,984 ChemoCentryx, Inc. shares in Q4 2022, an estimated $2.01M.
- ALPS Advisors first reported a position in ChemoCentryx, Inc. in Q4 2016 and held it in 21 quarters.
- ALPS Advisors's ChemoCentryx, Inc. position peaked at $7.71M in Q4 2020.
- 1 fund tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q4 2022.
Based on ALPS Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.